|
1
|
Sharma RA, Harris AL, Dalgleish AG,
Steward WP and O’Byrne KJ: Angiogenesis as a biomarker and target
in cancer chemoprevention. Lancet Oncol. 2:726–732. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Teo NB, Shoker BS, Martin L, Sloane JP and
Holcombe C: Angiogenesis in pre-invasive cancers. Anticancer Res.
22:2061–2072. 2002.PubMed/NCBI
|
|
3
|
Kieran MW and Billett A: Antiangiogenesis
therapy. Current and future agents. Hematol Oncol Clin North Am.
15:835–851. viii2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Carmeliet P and Jain RK: Angiogenesis in
cancer and other diseases. Nature. 407:249–257. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pour L, Hajek R, Buchler T, Maisnar V and
Smolej L: Angiogenesis and antiangiogenic cancer therapy. Vnitr
Lek. 50:930–938. 2004.(In Czech).
|
|
6
|
O’Reilly MS, Holmgren L, Shing Y, et al:
Angiostatin: a novel angiogenesis inhibitor that mediates the
suppression of metastases by a Lewis lung carcinoma. Cell.
79:315–328. 1994.PubMed/NCBI
|
|
7
|
O’Reilly MS, Boehm T, Shing Y, et al:
Endostatin: an endogenous inhibitor of angiogenesis and tumor
growth. Cell. 88:277–285. 1997.
|
|
8
|
Moses MA and Langer R: A metalloproteinase
inhibitor as an inhibitor of neovascularization. J Cell Biochem.
47:230–235. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rastinejad F, Polverini PJ and Bouck NP:
Regulation of the activity of a new inhibitor of angiogenesis by a
cancer suppressor gene. Cell. 56:345–355. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yancopoulos GD, Davis S, Gale NW, Rudge
JS, Wiegand SJ and Holash J: Vascular-specific growth factors and
blood vessel formation. Nature. 407:242–248. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jain RK: Molecular regulation of vessel
maturation. Nat Med. 9:685–693. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Leung DW, Cachianes G, Kuang WJ, Goeddel
DV and Ferrara N: Vascular endothelial growth factor is a secreted
angiogenic mitogen. Science. 246:1306–1309. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kim KJ, Li B, Winer J, et al: Inhibition
of vascular endothelial growth factor-induced angiogenesis
suppresses tumour growth in vivo. Nature. 362:841–844. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ferrara N and Davis-Smyth T: The biology
of vascular endothelial growth factor. Endocr Rev. 18:4–25. 1997.
View Article : Google Scholar
|
|
15
|
Millauer B, Shawver LK, Plate KH, Risau W
and Ullrich A: Glioblastoma growth inhibited in vivo by a
dominant-negative Flk-1 mutant. Nature. 367:576–579. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Holash J, Davis S, Papadopoulos N, et al:
VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl
Acad Sci USA. 99:11393–11398. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kim ES, Serur A, Huang J, et al: Potent
VEGF blockade causes regression of coopted vessels in a model of
neuroblastoma. Proc Natl Acad Sci USA. 99:11399–11404. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gomez-Manzano C, Holash J, Fueyo J, et al:
VEGF Trap induces antiglioma effect at different stages of disease.
Neuro Oncol. 10:940–945. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zaiss AK and Muruve DA: Immunity to
adeno-associated virus vectors in animals and humans: a continued
challenge. Gene Ther. 15:808–816. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Herzog RW, Yang EY, Couto LB, et al:
Long-term correction of canine hemophilia B by gene transfer of
blood coagulation factor IX mediated by adeno-associated viral
vector. Nat Med. 5:56–63. 1999. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang L, Takabe K, Bidlingmaier SM, Ill CR
and Verma IM: Sustained correction of bleeding disorder in
hemophilia B mice by gene therapy. Proc Natl Acad Sci USA.
96:3906–3910. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ponnazhagan S, Mahendra G, Kumar S, et al:
Adeno-associated virus 2-mediated antiangiogenic cancer gene
therapy: long-term efficacy of a vector encoding angiostatin and
endostatin over vectors encoding a single factor. Cancer Res.
64:1781–1787. 2004. View Article : Google Scholar
|
|
23
|
Collins SA, Buhles A, Scallan MF, et al:
AAV2-mediated in vivo immune gene therapy of solid tumours. Genet
Vaccines Ther. 8:82010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Casanovas O, Hicklin DJ, Bergers G and
Hanahan D: Drug resistance by evasion of antiangiogenic targeting
of VEGF signaling in late-stage pancreatic islet tumors. Cancer
Cell. 8:299–309. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Paley PJ, Staskus KA, Gebhard K, et al:
Vascular endothelial growth factor expression in early stage
ovarian carcinoma. Cancer. 80:98–106. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Heist RS, Zhai R, Liu G, et al: VEGF
polymorphisms and survival in early-stage non-small cell lung
cancer. J Clin Oncol. 26:856–862. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Johnson DE, Lee PL, Lu J and Williams LT:
Diverse forms of a receptor for acidic and basic fibroblast growth
factors. Mol Cell Biol. 10:4728–4736. 1990.PubMed/NCBI
|
|
28
|
Basilico C and Moscatelli D: The FGF
family of growth factors and oncogenes. Adv Cancer Res. 59:115–165.
1992. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ferrara N: VEGF and the quest for tumour
angiogenesis factors. Nat Rev Cancer. 2:795–803. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ferrara N and Alitalo K: Clinical
applications of angiogenic growth factors and their inhibitors. Nat
Med. 5:1359–1364. 1999. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
Folkman J: Angiogenesis in cancer,
vascular, rheumatoid and other disease. Nat Med. 1:27–31. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Van Hinsbergh VW, Collen A and Koolwijk P:
Angiogenesis and anti-angiogenesis: perspectives for the treatment
of solid tumors. Ann Oncol. 10(Suppl 4): S60–S63. 1999.PubMed/NCBI
|
|
33
|
Kuo CJ, Farnebo F, Yu EY, et al:
Comparative evaluation of the antitumor activity of antiangiogenic
proteins delivered by gene transfer. Proc Natl Acad Sci USA.
98:4605–4610. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ferrara N, Chen H, Davis-Smyth T, et al:
Vascular endothelial growth factor is essential for corpus luteum
angiogenesis. Nat Med. 4:336–340. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Gerber HP, Vu TH, Ryan AM, Kowalski J,
Werb Z and Ferrara N: VEGF couples hypertrophic cartilage
remodeling, ossification and angiogenesis during endochondral bone
formation. Nat Med. 5:623–628. 1999. View
Article : Google Scholar
|
|
36
|
Gerber HP, Kowalski J, Sherman D, Eberhard
DA and Ferrara N: Complete inhibition of rhabdomyosarcoma xenograft
growth and neovascularization requires blockade of both tumor and
host vascular endothelial growth factor. Cancer Res. 60:6253–6258.
2000.
|
|
37
|
Folkman J: Antiangiogenic gene therapy.
Proc Natl Acad Sci USA. 95:9064–9066. 1998. View Article : Google Scholar
|
